Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mefenorex (Rondimen).

J Engel, G Kristen, A Schaefer

    Drug and Alcohol Dependence
    |June 1, 1986
    PubMed
    Summary
    This summary is machine-generated.

    Mefenorex demonstrates therapeutic efficacy for obesity treatment with good tolerability and no reported abuse or public health issues. Preclinical and clinical data suggest a low potential for abuse, unlike amphetamine.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Conflicts of interest in electrophysiology and devices presentations.

    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology·2022
    Same author

    Defect-Induced Water Bilayer Growth on Anatase TiO<sub>2</sub>(101).

    Langmuir : the ACS journal of surfaces and colloids·2018
    Same author

    Analysis of Minimally Invasive Left Thoracotomy HVAD Implantation - A Single-Center Experience.

    The Thoracic and cardiovascular surgeon·2018
    Same author

    A randomized, controlled, double-blind, multi-center trial to evaluate the efficacy and safety of a liquid containing ivy leaves dry extract (EA 575<sup>®</sup>) vs. placebo in the treatment of adults with acute cough.

    Die Pharmazie·2018
    Same author

    Integration of Murine and Human Studies for Mapping Periodontitis Susceptibility.

    Journal of dental research·2018
    Same author

    Nanoscale analysis of the oxidation state and surface termination of praseodymium oxide ultrathin films on ruthenium(0001).

    Ultramicroscopy·2017
    Same journal

    Cannabinoid (CB) 1 receptor antagonists block fentanyl conditioned place preference but not fentanyl antinociception.

    Drug and alcohol dependence·2026
    Same journal

    Opioid use disorder and hospital readmission in the United States from 2010 to 2022: Primary reasons and the complex interplay of comorbid conditions.

    Drug and alcohol dependence·2026
    Same journal

    Impact of medicaid waivers on medication for opioid use disorders in residential facilities: Evidence from twenty-five states.

    Drug and alcohol dependence·2026
    Same journal

    Mental and somatic multimorbidity among individuals with alcohol use disorder: A sex-stratified registry study.

    Drug and alcohol dependence·2026
    Same journal

    Monitoring novel psychoactive substance trends on social media: Analysis of discussions and dashboard implementation.

    Drug and alcohol dependence·2026
    Same journal

    A meta-analysis on the relationship between cultural identity and substance use among indigenous youth.

    Drug and alcohol dependence·2026
    See all related articles

    Area of Science:

    • Pharmacology
    • Psychopharmacology
    • Public Health

    Background:

    • Mefenorex, a centrally acting compound, was considered by a World Health Organization (WHO) Expert Committee in 1985.
    • Its therapeutic efficacy and tolerability in obesity treatment have been demonstrated.
    • Concerns regarding potential abuse and public health impact are relevant for psychotropic substance scheduling.

    Purpose of the Study:

    • To evaluate the therapeutic efficacy and safety profile of mefenorex.
    • To assess the potential for abuse and associated public health issues.
    • To provide data relevant to its consideration under the Convention on Psychotropic Substances.

    Main Methods:

    • Review of preclinical and clinical studies.
    • Analysis of reported cases of abuse, trafficking, and manufacturing.

    Related Experiment Videos

  • Assessment of public health and social problem reports.

    • Main Results:

    • Mefenorex is an effective adjunctive treatment for obesity over limited periods.
    • The compound is well-tolerated with minimal central stimulant activity.
    • No reports of actual abuse, illicit trafficking, or clandestine manufacturing exist.
    • Preclinical and clinical data do not indicate a significant abuse potential comparable to amphetamines.
    • Studies show no association with pulmonary hypertension.
    • No public health or social problems have been linked to mefenorex use.

    Conclusions:

    • Mefenorex is a well-tolerated anorectic agent with demonstrated therapeutic efficacy for obesity.
    • Current data suggest a low risk of abuse and no significant public health concerns.
    • Its profile supports its use as an adjunctive treatment for obesity.